featured
International Delphi Consensus on the Management of AQP4-IgG–Seropositive NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurology(R) Neuroimmunology & Neuroinflammation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
Neurol Neuroimmunol Neuroinflamm 2023 Jul 01;10(4)xx, F Paul, R Marignier, J Palace, G Arrambide, N Asgari, JL Bennett, BAC Cree, J De Sèze, K Fujihara, HJ Kim, R Hornby, S Huda, N Kissani, I Kleiter, S Kuwabara, M Lana-Peixoto, L Law, MI Leite, L Pandit, SJ Pittock, C Quan, S Ramanathan, D Rotstein, A Saiz, DK Sato, A Vaknin-DembinskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.